|
|
|
||||
| Home Help Feedback Subscriptions Archive Search Table of Contents | |||||
First published online November 27, 2006
doi: 10.1242/10.1242/jcs.03270
Commentary |
1 CIHR Group in Skeletal Development and Remodeling, Division of Oral Biology, and Department of Physiology and Pharmacology, Schulich School of Medicine and Dentistry, University of Western Ontario, Dental Sciences Building, London, ON N6A 5C1, Canada
2 Centre for Rheumatology and Connective Tissue Diseases, Royal Free and University College Medical School, University College London (Royal Free Campus), Rowland Hill Street, London, NW3 2PF, UK
* Author for correspondence (e-mail: Andrew.Leask{at}schulich.uwo.ca)
Accepted 20 September 2006
| Summary |
|---|
|
|
|---|
Key words: CCN1, CCN3, Connective tissue growth factor, Integrins, Signal transduction, CCN2
| Introduction |
|---|
|
|
|---|
|
The three prototypical members of the CCN family were originally identified
15 years ago (O'Brien et al., 1990
; Bradham et al., 1991
; Joliot et al., 1992
). Since their discovery, >800 papers on CCN2,
200 papers on CCN1 and
100 papers on CCN3 have been published. Substantially fewer papers have examined CCN4, CCN5 and CCN6. In part, progress in this field has been hampered by a lack of unrestricted, readily commercially available reagents, such as `gold standard' recombinant material and neutralizing antibodies. Consequently in vitro studies have used a variety of different protein sources, purification procedures and antibodies. Indeed, a major difficulty in the CCN field has been the purification of active proteins, presumably because of the presence of repeated cysteine residues, which require the use of mammalian expression systems such as baculovirus or stable cell lines.
Initially, it was believed that these proteins were classical growth factors, and that simple application of recombinant material to cells was sufficient to recapitulate the entire range of CCN-dependent activities. The collective work of many laboratories, and especially the recent development of transgenic and knockout mice, has resulted in a greater appreciation of the range and complexity of CCN action. Indeed, it is now established that the CCN proteins are not growth factors and thus should not be referred to as such. This fact was a principal driving force within the CCN community to rename each family member. We now appreciate that, although the CCN proteins indeed have some independent activity, they principally modify signaling of other molecules, the identity of which can widely vary, depending on the particular biological system. CCN proteins stimulate mitosis, adhesion, apoptosis, extracellular matrix production, growth arrest and migration of multiple cell types. As a result, they play essential roles in development, wound healing and disease. The reader is referred to a recent comprehensive book on this subject (Perbal and Takigawa, 2005
). Here, we summarize current knowledge of role and function of CCN family members in these processes.
| CCN receptors |
|---|
|
|
|---|
vß3. The integrins bound include the principal integrins mediating angiogenesis and matrix attachment, such as
vß3,
5ß1 and
6ß1 (Chen et al., 2000
or ß integrin subunits. Both CCN1 and CCN2 are ligands of integrins
IIß3 in platelets and
Mß2 in monocytes (Jedsadayanmata et al., 1999
|
6ß1 are required for CCN1 to induce apoptosis in fibroblasts (Todorovicc et al., 2005| CCN proteins: role in adhesion, migration and signaling |
|---|
|
|
|---|
Fibroblasts plated on CCN2 activate the ERK pathway, which is required for their ability to attach to CCN2 (Chen, Y. et al., 2004
). Unlike cells adhering to fibronectin, fibroblasts adhering to CCN1 or CCN2 need not spread properly or generate actin fiber networks and phosphorylate focal adhesion kinase (FAK) (Chen, Y. et al., 2004
; Latinkic et al., 2003
). However, in some systems, such mature cell spreading can occur, and FAK phosphorylation occurs in response to CCN1, CCN2 and CCN3 (Li et al., 2002
; Chen, C. C. et al., 2001
). Intriguingly, immobilized recombinant CCN2 regulates migration of mesangial cells (Blom et al., 2001
) by promoting dephosphorylation of FAK (Crean et al., 2004
). Furthermore, CCN2-deficient mouse embryonic fibroblasts (MEFs) show defects in cell adhesion to fibronectin, including a significant reduction in FAK and ERK phosphorylation and delays in cell spreading and formation of actin stress fibers (Chen, Y. et al., 2004
).
In normal mouse embryo fibroblasts CCN2 is located within a complex composed of fibronectin and the fibronectin receptors, integrin
4ß1 and integrin
5ß1 and syndecan 4 (Chen, Y. et al., 2004
). Although likely, it is not clear whether other CCN molecules are also present in a complex of matrix and matrix receptors. One important physiological function of CCN proteins therefore appears to be to integrate cellular adhesion responses with the extracellular matrix environment, which is consistent with the proposed crucial role of CCN family members as adapter molecules integrating signaling between extracellular ligands and their receptors (Perbal, 2004
) (Fig. 2). Note, however, that although the observations discussed above suggest that CCN proteins have some inherent adhesive ability, their physiological function may be to modify, rather than be the immediate cause of, cellular adhesive responses.
|
| CCNs as co-factors for the ECM, growth factors and cytokines |
|---|
|
|
|---|
Consistent with the notion that CCN proteins promote signaling from growth factors is the observation that CCN1 does not possess mitogenic activity on its own, but rather enhances that of FGF and PDGF (Kireeva et al., 1996
). Similarly, CCN2 also enhances FGF- or EGF-induced DNA synthesis, but lacks mitogenic activity alone (Kireeva et al., 1997
; Grotendorst and Duncan, 2005
). CCN2 induces differentiation of myofibroblasts and increased collagen synthesis in concert with EGF, insulin-like growth factor 2 or insulin (Grotendorst et al., 2004
; Gore-Hyer et al., 2003
). Moreover, although not mitogenic on its own, CCN3 enhances basic-FGF-induced DNA synthesis and upregulates matrix metalloproteinase (MMP)-1 and PAI-1 expression (Lafont et al., 2005a
; Lin, C. et al., 2005
). In some studies, however, CCN2 has been shown to possess independent yet modest proliferative activity (
20% above control) (Asano et al., 2005
). The proliferative activity of CCN2 resides in domain IV and acts through Ras/MEK/ERK signaling (Gao et al., 2004
).
Significantly, CCN3 promotes FGF- and PDGF-mediated proliferation of C2C12 myoblast cells in an integrin-dependent fashion (Lafont et al., 2005a
). Through integrins, CCN proteins thus probably modify signaling responses to other proteins and, in principle, CCN molecules could modify a wide range of signal transduction pathways. A corollary of this is that CCN proteins need not necessarily have independent activity; their physiological effects may depend on the action of the particular partner with which the CCN proteins interact.
| CCN proteins in tissue repair and fibrosis |
|---|
|
|
|---|
-smooth muscle actin (
-SMA) and type I collagen (Shi-wen et al., 2006a
What inappropriate overexpression of CCN2 appears to do is to create an environment permissive for other stimuli to induce potent fibrotic responses. For example, overexpression of CCN2 results in fibrosis in mice that are otherwise resistant to developing pulmonary fibrosis in response to bleomycin (Bonniaud et al., 2004
), a model that is TGFß dependent (Zhao et al., 2002
). Simultaneous co-injection of CCN2 and TGFß causes sustained fibrotic responses in vivo, in contrast to application of TGFß alone, which causes only a transient fibrotic response that depends on the constant injection of ligand (Mori et al., 1999
). Indeed, although CCN2 is induced by TGFß and has long been hypothesized to be a downstream mediator of at least some of the effects of TGFß (Grotendorst, 1997
), recent evidence suggests that, in fact, CCN2 is an essential co-factor for and augments TGFß activity. In cultured Xenopus cells, CCN2 binds TGFß and enhances the ability of TGFß to bind TGFß receptors at low TGFß concentrations and hence indirectly affects Smad-responsive promoters (Abreu et al., 2002
).
CCN2 is constitutively expressed in fibrotic and embryonic fibroblasts independently of TGFß (Holmes et al., 2001
; Holmes et al., 2003
; Chen et al., 2006
). Experiments using Ccn2-/- MEFs have shown that loss of CCN2 results in an inability of TGFß to induce expression of approximately one-third of those mRNAs induced in Ccn2+/+ MEFs (Shi-wen et al., 2006a
). Consistent with the fact that CCN2 is required only for a subset of TGFß responses, Ccn2-/- MEFs show no impairment of the generic Smad pathway, emphasizing the relative selectivity of CCN2-dependent action (Shi-wen et al., 2006a
). In contrast to the lack of effect of loss of CCN2 expression on basal type I collagen and
-SMA expression, the ability of TGFß to induce these proteins is impaired in Ccn2-/- MEFs (Shi-wen et al., 2006a
). Intriguingly, the ability of TGFß to activate adhesive FAK/PI3kinase/Akt signaling is significantly impaired in Ccn2-/- fibroblasts, and this pathway is necessary for optimal induction of CCN2-dependent genes in wild-type MEFs (Shi-wen et al., 2006a
) (Fig. 2). Induction of
-SMA by TGFß has been shown to be FAK-, adhesion- and integrin-dependent (Thannickal et al., 2003
), which supports the notion that integrins are functional receptors for CCN2. Real-time PCR analysis has revealed that CCN2-dependent transcripts require CCN2 even at the extremely early time-points examined, before de novo induction of CCN2 protein (Shi-wen et al., 2006a
). Thus, in MEFs, CCN2 appears to be an essential cofactor required for TGFß to induce adhesive signaling responses and the correct signals for the formation of myofibroblasts. Indeed, the ability of TGFß to induce adhesion to the matrix is impaired in Ccn2-/- MEFs (Shi-wen et al., 2006a
). The results of these in vivo studies are therefore consistent with the in vivo experiments described above and confirm that CCN2 is required for maximal adhesive signaling in fibroblasts undergoing active tissue remodeling, such as in embryogenesis, fibrotic cells or tumor stroma (Blom et al., 2002
; Yang et al., 2005
). These results also suggest that CCN proteins act by enhancing signals not only from the extracellular matrix but also from growth factors through integrin-dependent pathways.
| CCN proteins play crucial roles in bone formation |
|---|
|
|
|---|
All CCN family members are expressed in chondrocytes and osteoblasts and are induced during fracture repair (Nakata et al., 2002
; French et al., 2004
; Schutze et al., 2005
; Parisi et al., 2006
), and each family member appears to respond differently to stimuli. For example, CCN1 expression and CCN6 expression decrease during chondrogenic differentiation, but only CCN6 RNA expression is reduced during osteogenic differentiation (Schutze et al., 2005
). In osteoblasts, TGFß enhances CCN1, CCN2 and CCN5 expression but decreases CCN4 expression (Parisi et al., 2006
). Intriguingly, CCN1 is activated by Wnt3A, and RNAi-mediated knockdown of CCN1 diminishes Wnt3A-induced osteogenic differentiation (Si et al., 2006
). This indicates that CCN1 is an essential mediator of Wnt signaling (Si et al., 2006
). Thus, although CCN proteins appear to have similar functions in vitro, each member may have different physiological effects in vivo depending on their different regulation and expression profiles.
Perhaps the most significant recent insights into the specific physiological roles of the CCN family have come from the generation of mutant mice lacking CCN2 (Ivkovic et al., 2003
) or CCN1 (Mo et al., 2002
). Ccn2-/- mice display severely malformed ribcages and die soon after birth owing to a failure to breathe (Ivkovic et al., 2003
). These mice exhibit impaired chondrocyte proliferation and proteoglycan production within the hypertrophic zone (Ivkovic et al., 2003
). Excessive chondrocytic hypertrophy and a concomitant reduction in endochondral ossification are also observed (Ivkovic et al., 2003
). Further support for the idea that CCN2 regulates bone formation in development comes from studies of transgenic mice that overproduce CCN2 under the control of the mouse type XI collagen promoter. These mice develop normally but show dwarfism within a few months of birth owing to a reduced bone density (Nakanishi et al., 2001
). The molecular basis for this deformity has not yet been explored; however, a possible explanation is that CCN2 overexpression results in abnormally premature ossification, before proper chondrocyte maturation. Point mutations in CCN6 have been linked to the autosomal recessive skeletal disease progressive pseudorheumatoid dysplasia (PPD), a human disease (Hurvitz et al., 1999
), resulting in juvenile-onset cartilage degeneration. Conversely, mice in which exons III, IV and V of CCN6 were deleted, resulting in absence of CCN6 expression, showed no apparent phenotype (Kutz et al., 2005
). In this study CCN6 expression was not detected anywhere in the mouse (Kutz et al., 2005
). Although it is possible that complete loss of CCN6 expression in ccn6-/- mice may have resulted in the compensatory overexpression of other CCN family members, it is also plausible that additional factors than CCN6 may be the cause of PPD.
| CCN family members contribute to angiogenesis and cancer |
|---|
|
|
|---|
vß3 (Leu et al., 2002
30% of those mice that die exhibit a complete failure in chorioallantoic fusion, whereas the remainder perish as a result of placental vascular insufficiency and compromised vessel integrity (Mo et al., 2002
Aberrant expression of the CCNs is associated with cancer and vascular disease (Pennica et al., 1998
; Gupta et al., 2001
; Rachfal et al., 2004
; Holloway et al., 2005
; Zhang et al., 2005
). For informative, focused reviews on the role of CCNs in cancer, the reader is referred elsewhere (Mendenez et al., 2003; Rachfal and Brigstock, 2005). Confirming a role for CCN1 in cancer, ectopic expression of CCN1 enhances the growth of ovarian cancer cells in liquid culture and increases tumorigenicity in nude mice, whereas inhibition of CCN1 expression decreases proliferation and increases apoptosis in these cells (Gery et al., 2005
). Similarly, patients with gastric adenocarcinomas display levels of CCN1 that correlate well with aggressive lymph node metastasis, more advanced tumor stage, histologically diffuse type, and early recurrence (Lin, M. et al., 2005
).
Treatment of mice with a CCN2-neutralizing antibody greatly decreases osteolytic bone metastasis, the appearance of microvasculature, and suppresses the growth of subcutaneous tumors (Shimo et al., 2006
). Similarly, in a recent study, anti-CCN2 antibody decreased tumor growth and metastasis and attenuated tumor angiogenesis and cancer cell proliferation in vitro and in vivo models of pancreatic cancer (Aikawa et al., 2006
). Conversely, CCN5, which lacks the pro-proliferative module IV (Fig. 1), suppresses proliferation and its expression is reduced in cancers (Mason et al., 2004
). Intriguingly, expression of CCN3, although it possesses module IV, inversely correlates with tumorigenicity (Gupta et al., 2001
); since CCN3 binds connexin, it might promote the formation of gap junctions, which would reduce metastasis (Gellhaus et al., 2004
; Fu et al., 2004
). RNAi-mediated CCN6 inhibition promotes neoplastic progression, as visualized by increased anchorage-independent growth of human mammary epithelial cells, and elevated responsiveness to the mitogen insulin-like growth factor 1 (Zhang et al., 2005
). These results suggest that, although CCN family members share similar structures, their activities differ, presumably because of differences in their amino acid sequences and the proteins with which they interact. Furthermore, they suggest that altering the relative expression levels of individual CCN family members may have profound physiological and pathological effects.
| CCN gene regulation |
|---|
|
|
|---|
The ability of TGFß to induce CCN2 also requires protein kinase C and the Ras/MEK/ERK MAP kinase cascade (Chen et al., 2002
; Stratton et al., 2002
; Leask et al., 2003
) (Fig. 3). As in the case of other TGFß-responsive promoters that do not require the transcription factor AP-1, the induction of CCN2 by TGFß is antagonized by hyperactive AP-1 or Jun N-terminal kinase (JNK) (Leask et al., 2003
), because of the ability of active Jun to bind to Smads off DNA and inhibit Smads from interacting with the target DNA sequences (Verrecchia et al., 2001
). Intriguingly, the TGFß-mediated suppression of CCN3 expression is Smad independent but JNK dependent (Lafont et al., 2002
). The Smad element of the CCN2 promoter acts in concert with a tandem repeat of an ETS element (Leask et al., 2001
; Leask et al., 2003
). Endogenous Ets-1 transcription factor binds this element and is required for the induction of CCN2 by TGFß (van Beek et al., 2006
) (Fig. 2). Additional elements that contribute primarily to the basal transcriptional activity of the CCN2 promoter include a BCE-1 (basal control element 1) site and an Sp1 site (Holmes et al., 2001
; Holmes et al., 2003
; Chen et al., 2002
). The BCE-1 site also mediates the Ras/MEK/ERK-dependent response of the CCN2 promoter to endothelin 1 (Shi-wen et al., 2004
). Because endothelin is induced by TGFß (Rodriguez-Pascual et al., 2003
; Shi-wen et al., 2006b
), BCE-1 is probably indirectly involved in the induction of CCN2 by TGFß. Befitting a gene associated with angiogenesis, CCN2 is also induced by hypoxia through a hypoxia-inducible factor (HIF)-response element (Higgins et al., 2004
) (Fig. 3). In addition, CCN2 mRNA displays a degree of post-transcriptional regulation, primarily concerned with message stability. Thus there is a minimal 84-nucleotide element in the CCN2 mRNA 3'-UTR, which acts as a cis-acting element of structure-anchored repression (CAESAR) in a chondrocyte cell line (Kubota et al., 2000
) and also contributes to hypoxia-mediated CCN2 mRNA stabilization (Kondo et al., 2006
) (Fig. 3). Post-transcriptional regulatory mechanisms might similarly control the expression of other CCN family members.
CCN2 overexpression is a fairly robust biological marker for fibrotic diseases (Blom et al., 2002
). An ELISA that detects CCN2 in biological fluids is a very useful marker of the severity of fibrosis in diseases such as scleroderma and diabetic nephropathy (Dziadzio et al., 2005
; Nguyen et al., 2006
). CCN2 overexpression in the fibrotic disease scleroderma is independent of TGFß and Smads but dependent on BCE-1 and Sp1 (Abraham et al., 2000
; Holmes et al., 2001
; Holmes et al., 2003
). It is likely therefore to depend in part on the expression of endothelin 1. Indeed, antagonism of the A and B endothelin receptors significantly reduces the overexpression of CCN2 in scleroderma (X. Shi-wen, A.L. and D.J.A., unpublished results); aberrant endothelin-1-dependent overexpression of CCN2 thus appears to be an important hallmark of fibrogenesis (Leask and Abraham, 2004
). Whether endothelin induces expression of other CCN family members is not known.
| Conclusion |
|---|
|
|
|---|
| Footnotes |
|---|
| References |
|---|
|
|
|---|
Abraham, D. J., Shiwen, X., Black, C. M., Sa, S., Xu, Y. and Leask, A. (2000). Tumor necrosis factor alpha suppresses the induction of connective tissue growth factor by transforming growth factor-beta in normal and scleroderma fibroblasts. J. Biol. Chem. 275, 15220-15225.
Abreu, J. G., Ketpura, N. I., Reversade, B. and De Robertis, E. M. (2002). Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-beta. Nat. Cell Biol. 4, 599-604.[Medline]
Aikawa, T., Gunn, J., Spong, S. M., Klaus, S. J. and Korc, M. (2006). Connective tissue growth factor-specific antibody attenuates tumor growth, metastasis, and angiogenesis in an orthotopic mouse model of pancreatic cancer. Mol. Cancer Ther. 5, 1108-1116.
Asano, M., Kubota, S., Nakanishi, T., Nishida, T., Yamaai, T., Yosimichi, G., Ohyama, K., Sugimoto, T., Murayama, Y. and Takigawa, M. (2005). Effect of connective tissue growth factor (CCN2/CTGF) on proliferation and differentiation of mouse periodontal ligament-derived cells. Cell Commun. Signal. 3, 11.[CrossRef][Medline]
Babic, A. M., Kireeva, M. L., Kolesnikova, T. V. and Lau, L. F. (1998). CYR61, a product of a growth factor-inducible immediate early gene, promotes angiogenesis and tumor growth. Proc. Natl. Acad. Sci. USA 95, 6355-6360.
Babic, A. M., Chen, C. C. and Lau, L. F. (1999). Fisp12/mouse connective tissue growth factor mediates endothelial cell adhesion and migration through integrin alphavbeta3, promotes endothelial cell survival, and induces angiogenesis in vivo. Mol. Cell. Biol. 19, 2958-2966.
Bartholin, L., Wessner, L. L., Chirgwin, J. M. and Guise, T. A. (2006). The human Cyr61 gene is a transcriptional target of transforming growth factor beta in cancer cells. Cancer Lett. doi: 10.1016/j.canlet.2006.02.019
Blom, I. E., van Dijk, A. J., Wieten, L., Duran, K., Ito, Y., Kleij, L., deNichilo, M., Rabelink, T. J., Weening, J. J., Aten, J. et al. (2001). In vitro evidence for differential involvement of CTGF, TGFbeta, and PDGF-BB in mesangial response to injury. Nephrol. Dial. Transplant. 16, 1139-1148.
Blom, I. E., Goldschmeding, R. and Leask, A. (2002). Gene regulation of connective tissue growth factor: new targets for antifibrotic therapy? Matrix Biol. 21, 473-482.[CrossRef][Medline]
Bonniaud, P., Margetts, P. J., Kolb, M., Haberberger, T., Kelly, M., Robertson, J. and Gauldie, J. (2003). Adenoviral gene transfer of connective tissue growth factor in the lung induces transient fibrosis. Am. J. Respir. Crit. Care Med. 168, 770-778.
Bonniaud, P., Martin, G., Margetts, P. J., Ask, K., Robertson, J., Gauldie, J. and Kolb, M. (2004). Connective tissue growth factor is crucial to inducing a profibrotic environment in "fibrosis-resistant" BALB/c mouse lungs. Am. J. Respir. Cell Mol. Biol. 31, 510-516.
Bork, P. (1993). The modular architecture of a new family of growth regulators related to connective tissue growth factor. FEBS Lett. 327, 125-130.[CrossRef][Medline]
Bradham, D. M., Igarashi, A., Potter, R. L. and Grotendorst, G. R. (1991). Connective tissue growth factor: a cysteine-rich mitogen secreted by human vascular endothelial cells is related to the SRC-induced immediate early gene product CEF-10. J. Cell Biol. 114, 1285-1294.
Brigstock, D. R., Steffen, C. L., Kim, G. Y., Vegunta, R. K., Diehl, J. R. and Harding, P. A. (1997). Purification and characterization of novel heparin-binding growth factors in uterine secretory fluids. Identification as heparin-regulated Mr 10,000 forms of connective tissue growth factor. J. Biol. Chem. 272, 20275-20282.
Brigstock, D. R., Goldschmeding, R., Katsube, K. I., Lam, S. C., Lau, L. F., Lyons, K., Naus, C., Perbal, B., Riser, B., Takigawa, M. et al. (2003). Proposal for a unified CCN nomenclature. Mol. Pathol. 56, 127-128.
Chen, C. C., Mo, F. E. and Lau, L. F. (2001). The angiogenic factor Cyr61 activates a genetic program for wound healing in human skin fibroblasts. J. Biol. Chem. 276, 47329-47337.
Chen, N., Chen, C. C. and Lau, L. F. (2000). Adhesion of human skin fibroblasts to Cyr61 is mediated through integrin alpha 6beta 1 and cell surface heparan sulfate proteoglycans. J. Biol. Chem. 275, 24953-24961.
Chen, N., Leu, S. J., Todorovic, V., Lam, S. C. and Lau, L. F. (2004). Identification of a novel integrin alphavbeta3 binding site in CCN1 (CYR61) critical for pro-angiogenic activities in vascular endothelial cells. J. Biol. Chem. 279, 44166-44176.
Chen, Y., Segarini, P., Raoufi, F., Bradham, D. and Leask, A. (2001). Connective tissue growth factor is secreted through the Golgi and is degraded in the endosome Exp. Cell Res. 271, 109-117.[CrossRef][Medline]
Chen, Y., Blom, I. E., Sa, S., Goldschmeding, R., Abraham, D. J. and Leask, A. (2002). CTGF expression in mesangial cells: involvement of SMADs, MAP kinase, and PKC. Kidney Int. 62, 1149-1159.[CrossRef][Medline]
Chen, Y., Abraham, D. J., Shi-Wen, X., Pearson, J. D., Black, C. M., Lyons, K. M. and Leask, A. (2004). CCN2 (connective tissue growth factor) promotes fibroblast adhesion to fibronectin. Mol. Biol. Cell 15, 5635-5646.
Chen, Y., Shi-wen, X., Eastwood, M., Black, C. M., Denton, C. P., Leask, A. and Abraham, D. J. (2006). Contribution of activin receptor-like kinase 5 (transforming growth factor betareceptor type I) signaling to the fibrotic phenotype of scleroderma fibroblasts. Arthritis Rheum. 54, 1309-1316.[CrossRef][Medline]
Crean, J. K., Furlong, F., Finlay, D., Mitchell, D., Murphy, M., Conway, B., Brady, H. R., Godson, C. and Martin, F. (2004). Connective tissue growth factor [CTGF]/CCN2 stimulates mesangial cell migration through integrated dissolution of focal adhesion complexes and activation of cell polarization. FASEB J. 18, 1541-1543.
Desnoyers, L., Arnott, D. and Pennica, D. (2001). WISP-1 binds to decorin and biglycan. J. Biol. Chem. 276, 47599-47607.
Dziadzio, M., Usinger, W., Leask, A., Abraham, D., Black, C. M., Denton, D. and Stratton, R. (2005). N-terminal connective tissue growth factor is a marker of the fibrotic phenotype in scleroderma. QJM 98, 485-492.
Ellis, P. D., Metcalfe, J. C., Hyvonen, M. and Kemp, P. R. (2003). Adhesion of endothelial cells to NOV is mediated by the integrins alphavbeta3 and alpha5beta1. J. Vasc. Res. 40, 234-243.[CrossRef][Medline]
Fataccioli, V., Abergel, V., Wingertsmann, L., Neuville, P., Spitz, E., Adnot, S., Calenda, V. and Teiger, E. (2002). Stimulation of angiogenesis by Cyr61 gene: a new therapeutic candidate. Hum. Gene Ther. 13, 1461-1470.[CrossRef][Medline]
French, D. M., Kaul, R. J., D'Souza, A. L., Crowley, C. W., Bao, M. Frantz, G. D., Filaroff, E. H. and Desnoyers, L. (2004). WISP-1 is an osteoblastic regulator expressed during skeletal development and fracture repair. Am. J. Pathol. 165, 855-867.
Fu, C. T., Bechberger, J. F., Ozog, M. A., Perbal, B. and Naus, C. C. (2004). CCN3 (NOV) interacts with connexin43 in C6 glioma cells: possible mechanism of connexin-mediated growth suppression. J. Biol. Chem. 279, 36943-36950.
Gao, R. and Brigstock, D. R. (2003). Low density lipoprotein receptor-related protein (LRP) is a heparin-dependent adhesion receptor for connective tissue growth factor (CTGF) in rat activated hepatic stellate cells. Hepatol. Res. 27, 214-220.[CrossRef][Medline]
Gao, R. and Brigstock, D. R. (2004). Connective tissue growth factor (CCN2) induces adhesion of rat activated hepatic stellate cells by binding of its C-terminal domain to integrin alpha(v)beta(3) and heparan sulfate proteoglycan. J. Biol. Chem. 279, 8848-8855.
Gao, R., Ball, D. K., Perbal, B. and Brigstock, D. R. (2004). Connective tissue growth factor induces c-fos gene activation and cell proliferation through p44/42 MAP kinase in primary rat hepatic stellate cells. J. Hepatol. 40, 431-438.[CrossRef][Medline]
Gellhaus, A., Dong, X., Propson, S., Maass, K., Klein-Hitpass, L., Kibschull, M., Traub, O., Willecke, K., Perbal, B., Lye, S. J. et al. (2004). Connexin43 interacts with NOV: a possible mechanism for negative regulation of cell growth in choriocarcinoma cells. J. Biol. Chem. 279, 36931-36942.
Gery, S., Xie, D., Yin, D., Gabra, H., Miller, C., Wang, H., Scott, D., Yi, W. S., Popoviciu, M. L., Said, J. W. et al. (2005). Ovarian carcinomas: CCN genes are aberrantly expressed and CCN1 promotes proliferation of these cells. Clin. Cancer Res. 11, 7243-7254.
Gore-Hyer, E., Pannu, J., Smith, E. A., Grotendorst, G. and Trojanowska, M. (2003). Selective stimulation of collagen synthesis in the presence of costimulatory insulin signaling by connective tissue growth factor in scleroderma fibroblasts. Arthritis Rheum. 48, 798-806.[CrossRef][Medline]
Grotendorst, G. R. (1997). Connective tissue growth factor: a mediator of TGF-beta action on fibroblasts. Cytokine Growth Factor Rev. 8, 171-179.[CrossRef][Medline]
Grotendorst, G. R. and Duncan, M. R. (2005). Individual domains of connective tissue growth factor regulate fibroblast proliferation and myofibroblast differentiation. FASEB J. 19, 729-738.
Grotendorst, G. R., Okochi, H. and Hayashi, N. (1996). A novel transforming growth factor beta response element controls the expressionof the connective tissue growth factor gene. Cell Growth Differ. 7, 469-480.[Abstract]
Grotendorst, G. R., Rahmanie, H. and Duncan, M. R. (2004). Combinatorial signaling pathways determine fibroblast proliferation and myofibroblast differentiation. FASEB J. 18, 469-479.
Gupta, N., Wang, H., McLeod, T. L., Naus, C. C., Kyurkchiev, S., Advani, S., Yu, J., Perbal, B. and Weichselbaum, R. R. (2001). Inhibition of glioma cell growth and tumorigenic potential by CCN3 (NOV). Mol. Pathol. 54, 293-299.
Higgins, D. F., Biju, M. P., Akai, Y., Wutz, A., Johnson, R. S. and Haase, V. H. (2004). Hypoxic induction of Ctgf is directly mediated by Hif-1. Am. J. Physiol. Renal Physiol. 287, F1223-F1232.
Holloway, S. E., Beck, A. W., Girard, L., Jaber, M. R., Barnett, C. C., Jr, Brekken, R. A. and Fleming, J. B. (2005). Increased expression of Cyr61 (CCN1) identified in peritoneal metastases from human pancreatic cancer. J. Am. Coll. Surg. 200, 371-377.[CrossRef][Medline]
Holmes, A., Abraham, D. J., Sa, S., Shiwen, X., Black, C. M. and Leask, A. (2001). CTGF and SMADs, maintenance of scleroderma phenotype is independent of SMAD signaling. J. Biol. Chem. 276, 10594-10601.
Holmes, A., Abraham, D. J., Chen, Y., Denton, C., Shi-wen, X., Black, C. M. and Leask, A. (2003). Constitutive connective tissue growth factor expression in scleroderma fibroblasts is dependent on Sp1. J. Biol. Chem. 278, 41728-41733.
Hoshijima, M., Hattori, T., Inoue, M., Araki, D., Hanagata, H., Miyauchi, A. and Takigawa, M. (2006). CT domain of CCN2/CTGF directly interacts with fibronectin and enhances cell adhesion of chondrocytes through integrin alpha5beta1. FEBS Lett. 580, 1376-1382.[CrossRef][Medline]
Hurvitz, J. R., Suwairi, W. M., Van Hul, W., El-Shanti, H., Superti-Furga, A., Roudier, J., Holderbaum, D., Pauli, R. M., Herd, J. K., Van Hul, E. V. et al. (1999). Mutations in the CCN gene family member WISP3 cause progressive pseudorheumatoid dysplasia. Nat. Genet. 23, 94-98.[CrossRef][Medline]
Igarashi, A., Okochi, H., Bradham, D. M. and Grotendorst, G. R. (1993). Regulation of connective tissue growth factor gene expression in human skin fibroblasts and during wound repair. Mol. Biol. Cell 4, 637-645.[Abstract]
Inoki, I., Shiomi, T., Hashimoto, G., Enomoto, H., Nakamura, H., Makino, K., Ikeda, E., Takata, S., Kobayashi, K. and Okada, Y. (2002). Connective tissue growth factor binds vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis. FASEB J. 16, 219-221.
Ivkovic, S., Yoon, B. S., Popoff, S. N., Safadi, F. F., Libuda de Stephenson, R. C., Daluiski, A. and Lyons, K. M. (2003). Connective tissue growth factor coordinates chondrogenesis and angiogenesis during skeletal development. Development 130, 2779-2791.
Jedsadayanmata, A., Chen, C. C., Kireeva, M. L., Lau, L. F. and Lam, S.C. (1999). Activation-dependent adhesion of human platelets to Cyr61 and Fisp12/mouse connective tissue growth factor is mediated through integrin alpha(IIb)beta(3). J. Biol. Chem. 274, 24321-24327.
Joliot, V., Martinerie, C., Dambrine, G., Plassiart, G., Brisac, M., Crochet, J. and Perbal, B. (1992). Proviral rearrangements and overexpression of a new cellular gene (nov) in myeloblastosis-associated virus type 1-induced nephroblastomas. Mol. Cell. Biol. 12, 10-21.
Kireeva, M. L., Mo, F. E., Yang, G. P. and Lau, L. F. (1996). Cyr61, a product of a growth factor-inducible immediate-early gene, promotes cell proliferation, migration, and adhesion. Mol. Cell. Biol. 16, 1326-1334.[Abstract]
Kireeva, M. L., Latinkic, B. V., Kolesnikova, T. V., Chen, C. C., Yang, G. P., Abler, A. S. and Lau, L. F. (1997). Cyr61 and Fisp12 are both ECM-associated signaling molecules: activities, metabolism, and localization during development. Exp. Cell Res. 233, 63-77.[CrossRef][Medline]
Kireeva, M. L., Lam, S. C. and Lau, L. F. (1998). Adhesion of human umbilical vein endothelial cells to the immediate-early gene product Cyr61 is mediated through integrin alphavbeta3. J. Biol. Chem. 273, 3090-3096.
Kondo, S., Kubota, S., Mukudai, Y., Moritani, N., Nishida, T., Matsushita, H., Matsumoto, S., Sugahara, T. and Takigawa, M. (2006). Hypoxic regulation of stability of connective tissue growth factor/CCN2 mRNA by 3'-untranslated region interacting with a cellular protein in human chondrosarcoma cells. Oncogene 25, 1099-1110.[CrossRef][Medline]
Kubota, S., Kondo, S., Eguchi, T., Hattori, T., Nakanishi, T., Pomerantz, R. J. and Takigawa, M. (2000). Identification of an RNA element that confers post-transcriptional repression of connective tissue growth factor/hypertrophic chondrocyte specific 24 ctgf/hcs24) gene: similarities to retroviral RNA-protein interactions. Oncogene 19, 4773-4786.[CrossRef][Medline]